Nanospectra is a medical device company pioneering a novel use of nanomedicine for selective thermal ablation.
Nanospectra is bringing a new technology model to market for tissue ablation that maximizes patient benefits while minimizing side effects.
Nanospectra was founded in 2001, on intellectual property from Rice University and collaborative research with scientists at MD Anderson Cancer Center. The company is headquartered in Houston, Texas.
Nanospectra is leveraging proprietary nanoshell technology for additional clinical applications and strategic partnerships.
Nanospectra’s proprietary ultra-focal technology platform has demonstrated its safety and efficacy in initial clinical trials and is viable for multiple applications including solid tumors, tissue and drug delivery. The company's lead product AuroLase®, is the first ultra-focal therapy for prostate cancer.
Nanospectra's ultra-focal approach maximizes treatment efficacy while minimizing side effects associated with current treatments, including surgery, radiation, and alternative focal therapies. Implementing a multi-prong growth strategy, Nanospectra is focusing on clinical advancements, exclusive partnering agreements and ongoing research and development.
Nanospectra is backed by Sirtex Medical, Scarlet Fire Private Investment, LP and others. The company raised $3M in a Series B-1 round on Sep 08, 2020. This brings Nanospectra's total funding to $8.2M to date.